Bayer Inc. has won further support from a Canadian court to block Fresenius Kabi Canada Ltd. from producing a generic version of the patented intravenous antibiotic drug Avelox IV (moxifloxacin) (Bayer Inc. v. Fresenius Kabi Canada Ltd.order made public).
The Federal Court of Canada refused to reconsider its May 2016 decision granting Bayer a prohibition order blocking Health Canada from approving the generic. Fresenius’ application for reconsideration was only an attempt to reargue the first ruling, Justice Henry S. Brown said in the Aug. 25 ruling, made public on Sept. 30.
“I am satisfied now, as I was ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.